Aktiesnakken — Juni 2013
-
Har du læst full text? De behandler med væsentligt lavere dosis end rituximab sc, derfor færre bivirkninger. De klarer infusionsbivirkninger med panodil og antihistamin!!!
-
De skriver at forsøget har dannet grundlag for Repeat behandling i rrms forsøget. Har de holdt RA data tilbage indtil rrms er på trapperne?
-
was consistent with that found in studies where anti-CD20 antibodies were administered intravenously
-
The results of our study have generated the data that allowed progression of repeat dosing of SC ofatu- mumab in multiple sclerosis and also support investigation of repeat dosing in patients with active RA.
-
I det nyeste Blood: Key points
Replacing rituximab with ofatumumab in 2nd-line therapy for intermediate grade lymphoma does not increase toxicity; ORR/CR are encouraging.
An ongoing randomized phase III trial will compare rituximab with ofatumumab, combined with chemotherapy, in relapsed or refractory DLBCL.
Jeg kan ikke linke, er på iPhone -
O-ICE og O-DHAP i 2nd Line NHL ORR 61% og CR 37%, ca 50% og 30% i højrisiko grupper
-
-
mornings
-
Zealand præsenterer ved jeffries idag
-
Genmab imorgen
-
det kan jo ikke fortsætte
-
Ja lidt farligt at de sender det logo ud på en stor kongres som jeffries. De andre firmaer kommer da til at grine lidt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind